Heparin-induced thrombocytopenia (HIT) is an unpredictable, life-threatening, immune-mediated reaction to heparin. Variation in human leukocyte antigen (HLA) genes is now used to prevent immunemediated adverse drug reactions. Combinations of HLA alleles and killer cell immunoglobulin-like receptors (KIR) are associated with multiple autoimmune diseases and infections. The objective of this study is to evaluate the association of HLA alleles and KIR types, alone or in the presence of different HLA ligands, with HIT. HIT cases and heparin-exposed controls were identified in BioVU, an electronic health record coupled to a DNA biobank. HLA sequencing and KIR type imputation using Illumina OMNI-Quad data were performed. Odds ratios for HLA alleles and KIR types and HLA*KIR interactions using conditional logistic regressions were determined in the overall population and by race/ethnicity. Analysis was restricted to KIR types and HLA alleles with a frequency greater than 0.01. The p values for HLA and KIR association were corrected by using a false discovery rate q<0.05 and HLA*KIR interactions were considered significant at p<0.05. Sixty-five HIT cases and 350 matched controls were identified. No statistical differences in baseline characteristics were observed between
cases and controls. The HLA-DRB3*01:01 allele was significantly associated with HIT in the overall population (odds ratio 2.81 [1.57-5 .02], p=2.1910 À4 , q=0.02) and in individuals with European ancestry, independent of other alleles. No KIR types were associated with HIT, although a significant interaction was observed between KIR2DS5 and the HLA-C1 KIR binding group (p=0.03). The HLA-DRB3*01:01 allele was identified as a potential risk factor for HIT. This class II HLA gene and allele represent biologically plausible candidates for influencing HIT pathogenesis. We found limited evidence of the role of KIR types in HIT pathogenesis. Replication and further study of the HLA-DRB3*01:01 association is necessary. KEY WORDS heparin-induced thrombocytopenia, HLA, killer cell immunoglobulin-like receptor (KIR), immunogenetics, pharmacogenomics, electronic health records. (Pharmacotherapy 2017;37 (9) :1164-1171) doi: 10.1002/phar.1983
Heparin-induced thrombocytopenia (HIT) is an antibody-mediated condition of platelet activation in patients receiving unfractionated heparin (UFH) and low molecular weight heparin (LMWH). 1 HIT develops in 0.5-5% of patients treated with heparin anticoagulants, has a greater than 30% mortality rate, and results in catastrophic thromboembolic complications, including life-and limb-threatening thrombosis. [2] [3] [4] [5] Further complicating the use of heparin anticoagulants, prevention of HIT-related thrombosis is currently possible only after manifestations of HIT are evident and the disease process has already begun. 6, 7 Clinical algorithms and laboratory tests are inadequate for evaluation of HIT risk prior to heparin administration. 8, 9 The inability to predict HIT thus represents a liability with heparin administration, and a priori identification of patients with a high HIT risk could make prevention of HIT possible.
The human leukocyte antigen (HLA) genes in the major histocompatibility complex (MHC) have emerged as a leading source of biomarkers of immune-mediated adverse drug reactions (ADRs), which can be translated into clinical care. 10, 11 Alleles from these HLA genes are powerful pharmacogenomic biomarkers for the prevention of previously unpredictable, immunemediated diseases. 10, [12] [13] [14] [15] [16] HLA alleles are now genotyped to guide drug treatment and prevent immune-mediated ADRs, moving personalized medicine toward reality. 12 Previous studies have implicated HLA-DR variation with the formation of platelet factor 4 (PF4)/heparin antibodies and HIT, 17, 18 suggesting that strong genetic influences on HIT risk might still be identified with HLA or immune-related genes in the MHC.
In addition to HLA alleles, killer immunoglobulin-like receptor (KIR) types have been observed to associate with disease alone or in interaction with HLA allele ligands. [19] [20] [21] KIRs act as receptors on natural killer (NK) cells, play a major role in the rejection of virus-infected or tumor-transformed cells, and are able to interact with particular class I HLA alleles. The objective of this study was to identify HLA alleles, KIR types, and HLA*KIR interactions associated with HIT. This study was conducted using HIT cases and heparin-exposed controls identified in an electronic health record (EHR) linked to a DNA repository.
Materials and Methods

Study Population
The study population was identified in BioVU, the Vanderbilt DNA databank that links DNA extracted from discarded blood samples to deidentified EHRs. 22 This study was approved by the institutional review board at Vanderbilt University as described previously. 22 An algorithm was developed to identify individuals with a diagnosis of HIT in the EHR as previously described. 18 The algorithm used ICD-9 diagnostic codes, laboratory results, and natural language processing 23, 24 to analyze narrative text in order to identify patients treated with UFH or LMWH who tested positive for PF4/heparin antibodies (optical density [OD] level > 0.7 absorbance units [AU] ). UFH or LMWH-treated controls were also identified in the EHR with a control algorithm that used similar techniques. Controls were selected in a 1:5 case:control ratio prior to genomic quality control. HIT cases were confirmed by chart review by at least two physician or pharmacist reviewers. HIT cases were scored with use of the 4Ts scoring system, which estimates the likelihood of HIT based on timing, magnitude, and potential causes of thrombocytopenia and presence of thrombosis and with a maximum 4Ts score of eight. 6, 25 Controls were matched to cases based on age, STRUCTURE-defined race (as described later), 26 and type of heparin exposure (UFH vs LMWH).
HLA Sequencing
High-resolution, four-digit HLA sequencing was performed for HLA-A, HLA-B, HLA-C, HLA-DR, HLA-DP, and HLA-DQ at the Institute for Immunology and Infectious Diseases (IIID) at Murdoch University in Perth, Australia. The IIID is accredited by the American Society for Histocompatibility and Immunogenetics (ASHI) and the National Association of Testing Authorities (NATA) and has extensive experience with sequencing the HLA genes included in large, multicenter trials using HLA sequence data. 12, 27 Specific HLA loci were polymerase chain reaction (PCR) amplified using sample specific molecular identifier (MID)-tagged primers that amplify polymorphic exons from class I (A, B, C exons 2 and 3) and class II (DQ, exons 2 and 3; DRB and DPB1, exon 1) HLA genes. MID-tagged primers have been optimized to minimize allele dropouts and primer bias. Amplified DNA products from unique MID tagged products (up to 48 MIDs) were pooled in equimolar ratios and subjected to library preparation, quantitation, and emulsion PCR suitable for entry into the 454 FLX sequencing pipeline. Clonally enriched beads were sequenced by using 454 Titanium chemistry on a 454 FLX+ sequencer. Sequences were separated by MID tags and alleles were called by using an in-house accredited HLA allele caller software pipeline that minimizes the influence of systematic sequencing errors in 454 data. Alleles were called using the latest international ImMunoGeneTics information system (IMGT) HLA allele database as the allele reference library. Sample to report integrity was tracked and checked using proprietary and accredited Laboratory Information and Management System (LIMS) and HLA analysis reporting software that performs comprehensive allele balance and contamination checks on the final dataset. All samples that were successfully typed were included in the study population.
KIR Imputation
Samples were genotyped by using the Illumina HumanOmni1-QUAD and HumanOmni5-QUAD BeadChip genome-wide platforms as previously described. 18 Imputation of KIR types and KIR A versus B haplotype was performed on genotype data imputed from single nucleotide polymorphisms (SNPs) present on the intersection of these platforms (n=730,803 SNPs). Before imputation, data were cleaned using the quality control pipeline developed by the eMERGE Genomics Working Group. 28 KIR imputation was then performed for samples using KIR*IMP (http://imp.mcri.edu.au/hla/). 29 KIR binding groups (HLA-Bw6 or Bw4 and HLA-C1 or C2) were determined for each sample corresponding to sequenced HLA-B and HLA-C alleles, respectively. KIR*IMP uses a random-forest model to impute KIR data based on reference panels with sequenced KIR loci and genotyped SNP data. 29 Using this model, KIR alleles and haplotypes can be generated from a population with unknown KIR types but known SNP genotypes. KIR*IMP is validated and highly accurate, allowing for the study of KIR in large cohorts with SNP-level data, and enabling detailed investigation of the role of KIR in human disease.
Definition and Adjustment for Race/Ethnicity
Samples were classified as being of European or African descent using ancestry informative markers (AIMs) input into STRUCTURE using Hapmap reference populations. 26 Principal component (PC) analyses were also performed on AIMs using the EIGNESTRAT method implemented in PLINK. 30, 31 To minimize confounding by population stratification, association analyses were adjusted for the first two PCs and performed in both the overall population and by STRUCTURE-defined race.
Statistical Analysis
Differences in characteristics between cases and controls were determined using chi-square and t tests. The association of HIT with sequenced HLA alleles, imputed KIR types, and KIR haplotypes was tested, followed by the interaction of KIR types with HLA-Bw6/Bw4 and HLA-C1/C2. Tests of association with HIT were performed using logistic regression in a dominant model adjusted for age, gender, type of heparin anticoagulant (UFH vs LMWH), and PCs 1 and 2 for all SNPs in a total of 462 individuals by STRUCTURE-defined race. Multivariable logistic regression models were used to estimate odds ratios (ORs) and 95% confidence intervals for HIT, assess HLA*KIR interactions, and calculate synergy indices (SIs) for an estimate of multiplicative HLA*KIR interactions. 32 
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In the absence of an interaction effect, the SI equals 1. The same statistical models were used in an HLA*KIR interaction analysis that included pairwise testing of KIR types by HLABw6/Bw4 subgroup and by HLA-C1/C2 subgroup in multivariate logistic regressions. HLA and KIR association analyses were performed in non-European race/ethnic groups, but there was very little power to detect such associations. In a supplementary analysis, HLA and KIR alleles were also tested for association with 4Ts score among HIT cases using similar multivariable linear regressions. HLA alleles and KIR types were tested only if their allele frequency was greater than 0.01. HLA alleles were tested for deviation from Hardy-Weinberg equilibrium (HWE) and alleles with HWE p<0.01 were removed from further analyses. In order to determine linkage of class II allelic associations with HLA-DRB3*01:01, large haplotype reconstruction was used to classify carriers of HLA-DRB1*03:01 and HLA-DRB1*13:01 as being with or without HLA-DRB3*01:01. Logistic regression of the phenotype was then performed with cases split into those carrying HLA-DRB3*01:01 and those with HLA-DRB1*03:01 or HLA-DRB1*13:01 without HLA-DRB3*01:01. KIR and HLA associations with a false discovery rate (FDR) adjusted q value < 0.05 were considered significant. Significance for interaction analyses was considered at p<0.05. All statistical analyses were performed using PLINK 31 and SAS 9.3 (SAS, Cary, NC).
Results
A total of 65 HIT cases were identified from BioVU and matched to 350 controls ( Table 1) . The majority of cases were treated with UFH rather than LMWH, and the mean 4Ts score for HIT cases was 5.1 (standard deviation [SD] 0.9). No significant differences were observed in baseline characteristics between cases and controls. A total of 99 HLA alleles and 13 KIR types with frequencies greater than 0.01 were identified. No HLA alleles or KIR types significantly departed from HWE (p<0.01). Details of allele frequencies, genotype distributions, and HWE tests are provided in Appendix S1.
In the overall population, the HLA-DRB3*01:01 allele was significantly associated with HIT (OR 2.81 [1.57-5.02], p=2.10910 À4 , q=0.02) (Figure 1 ). When the analysis was performed by race, the HLA-DRB3*01:01 allele was significantly associated with HIT in individuals with STRUCTURE-defined European ancestry (OR 3.00 [1.59-5.62], p=2.67910 À4 , q=0.015). We found a nominal association between the number of HLA-DRB3*01:01 copies and 4Ts score among HIT cases (b=0.48, p=0.02). Seven other class I and II HLA alleles were nominally associated (p<0.05 but q>0.5) with HIT in the overall population and five other HLA alleles were nominally associated with HIT in individuals with primarily European ancestry. No HLA associations were observed in any non-European race/ethnic group, but there was very little power to detect such associations. Further details of the HLA association analysis are presented in Appendices S2 and S3.
Due to linkage of HLA-DRB3*01:01 with HLA-DRB1*03:01 and HLA-DRB1*13:01, large haplotype reconstruction was used to classify carriers of HLA-DRB1*03:01 and HLA-DRB1*13:01 as being with or without HLA-DRB3*01:01. Logistic regression was performed with the cases split into those carrying HLA-DRB3*01:01 and those with HLA-DRB1*03:01 or HLA-DRB1*13:01 without HLA-DRB3*01:01. In this analysis, there was no evidence of an association between HIT and HLA-DRB1*03:01 or HLA- 
Discussion
An original immunogenetic association study for HIT using an EHR-coupled DNA biobank is presented. Our results provide further evidence 
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PHARMACOTHERAPY Volume 37, Number 9, 2017 of the contribution of variation in the HLA-DR locus to HIT pathophysiology and implicate a specific HLA allele, HLA-DRB3*01:01, as a risk factor for HIT. Our analyses suggest that carriage of HLA-DRB3*01:01 is associated with HIT, and this association is not linked to carriage of HLA-DRB1*03:01 or HLA-DRB1*13:01. Our observed association is consistent with previous reports of an association between HIT and class II alleles, and these observations provide further insights into the immunopathology of HIT. Limited evidence was found that KIR types are associated with HIT, including the observation of an interaction between KIR2DS5 and HLA-C1 KIR ligand groups. To our knowledge, this is the first study to examine the role of KIR in HIT and the first study to implicate a specific HLA allele in HIT risk. Despite decades of research into the immunopathology of HIT, there is a fundamental knowledge gap regarding the cause of HIT. 33, 34 The causative immune cell types and the impetus for antibody formation have yet to be identified. The clinical significance of "nonpathogenic" PF4/ heparin antibodies remains unclear, and the molecular basis that distinguishes them from "pathogenic" PF4/heparin antibodies is also unknown. 35 The role of T cells in HIT and their involvement in PF4/heparin antibody production continues to be controversial and complicated by the fact that HIT displays characteristics of both an innate and adaptive immune reaction. Emerging evidence also suggests a key role of marginal zone B cells in T-cell-independent antibody production, as well as bacterial infection as an HIT sensitization event. 34, 36 The observed association between HIT and HLA-DRB3*01:01 suggests the involvement of Tcell-dependent PF4/heparin antibody formation. HLA-DR in the MHC region provides a particularly attractive candidate gene for HIT because class II HLA molecules are directly involved in the adaptive immune response resulting in antibody formation. Class II HLA alleles such as HLA-DR are central to antibody formation and HIT is caused by the formation of PF4/heparin antibodies. HLA-DRB3*01:01 is associated with fetomaternal alloimmune thrombocytopenia, and this allele likely mediates the presentation of HPA-1a peptides and subsequent production of anti-HPA-1a alloantibodies. 37, 38 PF4 has been shown to promote monocyte survival and induce monocyte differentiation into macrophages that lack the HLA-DR antigen. 39 We have also previously observed in a genome-wide association study (GWAS) that SNPs in HLA-DR are associated with HIT. 18 However, this GWAS was conducted in the same population as the present study and should not be considered an independent replication of these results. The present study investigates sequenced HLA alleles rather than SNPs, allowing for the identification of obligate HLA alleles or combinations of alleles necessary for HIT. The present study also examines the association of KIR types and HLA*KIR interactions, which is not possible using SNPlevel GWAS data. Finally, the HLA-DR3 serotype (HLA-DRB1*03:01) has been associated with thrombotic thrombocytopenic purpura and HLA-DR3 expression has been associated with the formation of PF4/heparin antibodies. 17, 40 The observed lack of association between HIT and KIR types is also consistent with a T-celldependent pathogenic model of HIT. KIR ligands are found exclusively among HLA class I alleles and the association of an HLA class II allele suggests the absence of a role of KIR types and, thus, NK cells in HIT. This analysis investigated all available combinations of KIR ligands and HLA-C1/C2 and Bw4/Bw6 binding groups and thus was not based on known predicted receptor/ligand interactions. The observed interaction between KIR2DS5 and the HLA-C1 binding group should be interpreted with caution as neither the HLA-C1 binding group nor any class I HLA allele was associated with HIT in our study. Neither HLA-C1 nor HLA-C2 has been shown to bind KIR2DS5, which does not have a well-known HLA ligand group. KIR2DS5 was also not associated with HIT, suggesting a limited or nonexistent role of KIR types in the immunogenetics of HIT.
There were several limitations in our study. The number of HIT cases was small, which may have limited our power to detect an HLA or KIR association with HIT. We were able to investigate associations only in individuals with primarily European ancestry and the results cannot be generalized to other race/ethnic groups, given the small sample sizes in our study population. However, the presence of the significantly associated HLA-DRB3*01:01 allele indicates that this number was sufficient to identify HLA associations. In this study, only common HLA alleles and KIR types were investigated, and any rare variation with modest effects on HIT pathogenesis would not be identified using our approach. The HIT cases were also retrospectively identified in an EHR, which precluded the acquisition of confirmatory functional assay testing for HIT.
Although the HIT cases were independently reviewed by multiple investigators, the possibility of classification bias in our observational HIT case and control cohort cannot be excluded. Although some misclassification is likely among HIT cases, the use of a high OD cutoff (0.7 AU) for PF4/heparin antibody testing and the prevalence in known HIT risk factors among cases, such as female sex, surgery, durations of exposure over 6 days, high 4Ts scores, and increased age suggest accurate classification among our cohort. The results of the KIR analysis rely on the accuracy of imputation from SNP-level data. Although the KIR genomic region was well covered on our GWAS platforms, some misclassification may be present in the imputation of KIR types. Finally, these results have not been replicated or prospectively validated in an independent population, and further research is required to confirm the HLA-DRB3*01:01 association with HIT.
In summary, an original immunogenetic association study for HIT using an EHR-coupled DNA biobank was described. The class II allele HLA-DRB3*01:01 was identified as a potential risk factor for HIT, providing additional evidence for the immune-pathogenesis of this unpredictable, potentially catastrophic consequence of heparin treatment. Our results require replication of the effect of HLA-DRB3*01:01 in independent populations to confirm this association. Limited evidence was obtained for the involvement of KIR types in HIT pathophysiology. As the inability to predict HIT remains a critical problem with heparin administration, immunogenetic variation might yield biomarkers that enable HIT prediction and preemptive genotyping strategies.
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